Choisissez la langue de votre document :
- bg - български
- es - español
- cs - čeština
- da - dansk
- de - Deutsch
- et - eesti keel
- el - ελληνικά
- en - English (Selected)
- fr - français
- ga - Gaeilge
- hr - hrvatski
- it - italiano
- lv - latviešu valoda
- lt - lietuvių kalba
- hu - magyar
- mt - Malti
- nl - Nederlands
- pl - polski
- pt - português
- ro - română
- sk - slovenčina
- sl - slovenščina
- fi - suomi
- sv - svenska
|
| Procedure : 2008/0045(COD) |
|
Document stages in plenary
| Document selected : A6-0346/2008 | ||||||
Texts tabled : A6-0346/2008 |  | Debates : PV 22/10/2008 - 2CRE 22/10/2008 - 2 |  | Votes : PV 22/10/2008 - 4.6Explanations of votes Explanations of votes |  | Texts adopted : P6_TA(2008)0510 |
| Debates | |
| Wednesday, 22 October 2008 - Strasbourg | OJ edition |
|
4.6. Variations to the terms of marketing authorisations for medicinal products (
| Legal notice - Privacy policy |